Total retinal fluid index (TRFI) during matched phase. (A) Macular TRFI in treatment agnostic (gray diamond), brolucizumab (blue circle), and aflibercept (red square) groups. (B) Central macular TRFI in treatment agnostic (gray diamond), brolucizumab (blue circle), and aflibercept (red square) groups. (C) Central subfield TRFI in treatment agnostic (gray diamond), brolucizumab (blue circle), and aflibercept (red square) groups. *P < 0.05 brolucizumab versus aflibercept in change from baseline.